Praxis Precision Medicines shares fall 1.89% intraday after Schall Law Firm investigates claims of false statements.

Praxis Precision Medicines, Inc. declined 1.89% in intraday trading, with the company facing an investigation by The Schall Law Firm for potential violations of securities laws. The investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The company reported mid-stage clinical results from the trial of vormatrigine, an anti-seizure medication, and admitted that more than half of patients experienced treatment-emergent adverse events.